Breakthroughs in Cancer Immunotherapy: An Overview of T Cell, NK Cell, Mφ, and DC-Based Treatments

Efforts to treat cancer using chimeric antigen receptor (CAR)-T therapy have made astonishing progress and clinical trials against hematopoietic malignancies have demonstrated their use. However, there are still disadvantages which need to be addressed: high costs, and side effects such as Graft-ver...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2023-12, Vol.24 (24), p.17634
Main Authors: Lee, Sunyoung, Kim, Tae-Don
Format: Article
Language:English
Subjects:
Antigens
Cancer therapies
cancer therapy
cancer treatment
cell-based immunotherapy
Chemotherapy
chimeric antigen receptor
Clinical trials
Cytokines
FDA approval
Humans
immune cell
Immune system
Immunotherapy
Immunotherapy, Adoptive - adverse effects
Killer Cells, Natural
Leukemia
Lymphocytes
Macrophages
Neoplasms
Patients
Radiation
T cell receptors
T-Lymphocytes
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Efforts to treat cancer using chimeric antigen receptor (CAR)-T therapy have made astonishing progress and clinical trials against hematopoietic malignancies have demonstrated their use. However, there are still disadvantages which need to be addressed: high costs, and side effects such as Graft-versus-Host Disease (GvHD) and Cytokine Release Syndrome (CRS). Therefore, recent efforts have been made to harness the properties of certain immune cells to treat cancer-not just T cells, but also natural killer (NK) cells, macrophages (Mφ), dendritic cells (DC), etc. In this paper, we will introduce immune cell-based cellular therapies that use various immune cells and describe their characteristics and their clinical situation. The development of immune cell-based cancer therapy fully utilizing the unique advantages of each and every immune cell is expected to enhance the survival of tumor patients owing to their high efficiency and fewer side effects.
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms242417634